<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04214366</url>
  </required_header>
  <id_info>
    <org_study_id>ACCO</org_study_id>
    <nct_id>NCT04214366</nct_id>
  </id_info>
  <brief_title>Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation</brief_title>
  <acronym>ACCO</acronym>
  <official_title>Adenoid Cystic Carcinoma and Carbon Ion Only Irradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heidelberg University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heidelberg University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Adenoid cystic tumors are rare tumors of the head and neck region. Despite their slow growth,
      re-irradiation is often necessary due to the high metastatic risk. Patients are usually
      irradiated with photons or, as here at the Heidelberg University Hospital, with a combination
      of carbon ions and photons. So far, there is no data from Europe available for the sole
      irradiation with carbon ions. The present ACCO (Adenoid Cystic Carcinoma and Carbon ion Only
      irradiation) study, a prospective, open-label, phase II, single-arm, investigator-initiated
      study, will therefore investigate the sole radiotherapy of carbon ions in this tumor entity.
      Irradiation is applied - significantly shorter than the combination therapy - in about 4
      weeks (22 fractions); patients are followed up for further 5 years after the start of
      therapy. Carbon ions alone are expected to increase local tumor control rates from 60% to 70%
      after 5 years (primary objective criterion of this study). In order to reject the null
      hypothesis with a power of 80% and a significance level of 5%, 175 patients are included
      (including a drop-out rate of 15%). Secondary objective criteria are progression-free
      survival, overall survival, acute and late toxicity, and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 15, 2019</start_date>
  <completion_date type="Anticipated">January 1, 2032</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2032</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from loco-regional progression</measure>
    <time_frame>at 5 years</time_frame>
    <description>Freedom from loco-regional tumor progression according to MR imaging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>at 3 and 5 years</time_frame>
    <description>Progression-free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>at 3 and 5 years</time_frame>
    <description>Overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute toxicities</measure>
    <time_frame>during and up to 6 weeks after radiotherapy</time_frame>
    <description>Acute toxicities according to NCI CTC AE (Version 5.0) (rate of toxicity &gt; 2 grade)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Late toxicities</measure>
    <time_frame>up to 5 years</time_frame>
    <description>Late toxicities according to NCI CTC AE (Version 5.0) (rate of toxicity &gt; 2 grade)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">314</enrollment>
  <condition>Adenoid Cystic Carcinoma</condition>
  <arm_group>
    <arm_group_label>Carbon Ion irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>22 x 3 Gy(RBE) Carbon Ions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bimodal Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 x 2 Gy photon IMRT and 8 x 3 Gy(RBE) Carbon ion boost</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carbon ion irradiation</intervention_name>
    <description>22 x 3 Gy(RBE) Carbon Ions</description>
    <arm_group_label>Carbon Ion irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Bimodal irradiation</intervention_name>
    <description>25 x 2 Gy photon IMRT + 8 x 3 Gy(RBE) Carbon ion boost</description>
    <arm_group_label>Bimodal Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed adenoid cystic carcinoma in the head and neck area

          -  Indication for irradiation:

          -  non-operable or

          -  R1/R2 resected or

          -  perineural sheat invasion (Pn+) or

          -  pT3/pT4

          -  Informed consent

          -  KI &gt; 60% or ECOG 0/1 (minimum: self-sufficiency, normal activity or work not possible)

          -  Age 18-80 years

        Exclusion Criteria:

          -  rejection of the study by the patient

          -  Patient is not able to consent

          -  Stage IV (distant metastases), except lung metastases &lt; 1cm

          -  lymph node involvement (clinical or pathological)

          -  Previous radiotherapy in the head and neck area

          -  Active medical implants for which there is no ion radiation authorization at the time
             of treatment (e.g., cardiac pacemaker, defibrillator, ...)

          -  Contraindication to MR imaging

          -  Simultaneous participation in another clinical study that could influence the outcome
             of this study or the other study

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Klaus Herfarth, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Heidelberg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Klaus Herfarth, Prof. Dr.</last_name>
    <phone>+49 6221 56 8201</phone>
    <email>klaus.herfarth@med.uni-heidelberg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Heidelberg, Radiooncology, HIT</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Herfarth, Prof. Dr.</last_name>
      <phone>+49 6221 568201</phone>
      <email>klausherfarth@med.uni-heidelberg.de</email>
    </contact>
    <investigator>
      <last_name>Klaus Herfarth, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>September 24, 2019</study_first_submitted>
  <study_first_submitted_qc>December 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>December 27, 2019</last_update_submitted>
  <last_update_submitted_qc>December 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Heidelberg University</investigator_affiliation>
    <investigator_full_name>Klaus Herfarth, MD</investigator_full_name>
    <investigator_title>Prof. Dr. Klaus Herfarth, Vice chair Dept. of Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>carbon ion</keyword>
  <keyword>heavy ion</keyword>
  <keyword>salivary gland tumor</keyword>
  <keyword>ACC</keyword>
  <keyword>Radiation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Adenoid Cystic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/66/NCT04214366/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

